Alzheimer’s Disease Treatments and Expectations

Research Objectives:

  • Understand the current treatment landscape for Alzheimer’s Disease patients
  • Explore what physicians know about and expect for products in development for Alzheimer’s Disease

Method: 9-minute MicroSurvey via InCrowd
Crowds: US Neurologists
Sample Size: n=100
Fielding Period: March 10-13, 2019
Screening Criteria:
Qualified respondents are US-based neurologists who:

  • Treat at least 10 Alzheimer’s Disease patients in a typical month
  • Are at least somewhat knowledgeable about products in development for the treatment of Alzheimer’s Disease

One key finding:

  • Responding neurologists tend to treat over 30 Alzheimer’s patients a month across all severity levels (39% mild, 38% moderate, 23% severe).

Download the full report now!

Please fill out the form below to access this content

This field is for validation purposes and should be left unchanged.

Related Resources

Why Diversity Matters to Patients

Why Diversity Matters to Patients

How does a diverse patient audience feel about representation among their own physicians? Is the diversity outlook improving among healthcare professionals? Find out in our latest report from the 2023 Pharma Market Research Conference. We examined: Satisfaction with...

read more
ASH 2022 Real-Time Round-Up

ASH 2022 Real-Time Round-Up

The 2022 Annual Meeting of the American Society of Hematology (ASH) took place in person from December 10th to the 13th. InCrowd wanted to learn from those Hematologists and Hematology-Oncologists who attended these two objectives: Explore which condition had the most...

read more